The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index; 41 of the 65 sources its claims cite were checked for support.
Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study
Open accessAbstract
This nationally representative cohort study assessed how racial/ethnic differences in SGLT2i and GLP-1RA use vary by payer after adjustment for socioeconomic and healthcare access factors.
Overview
CoChat Summary
TL;DR
In a nationally representative cross-sectional analysis of adults with diabetes, racial/ethnic disparities in SGLT2i/GLP1ra use varied by insurance type and were largest among people with private insurance. Medicaid enrollees had the lowest overall use, but no statistically significant racial/ethnic disparity.
Key findings
- The study included 4,997 adults, representing about 24.8 million US adults annually with diabetes; mean age was 63.6 years, 48.8% were female, 33.5% had private insurance, 56.8% Medicare, and 9.8% Medicaid.
- Overall, 12.9% used at least one SGLT2i or GLP1ra; use was highest with private insurance (17.3%), then Medicare (10.9%), and lowest with Medicaid (9.9%).
- In the fully adjusted model, White individuals with private insurance had higher use than non-White individuals (16.1% vs 8.3%, p < 0.001); the disparity was smaller for Medicare (14.7% vs 11.0%, p = 0.04) and not significant for Medicaid (10.0% vs 9.0%, p = 0.74).
- In unadjusted models, White vs non-White odds of medication use were OR 2.42 (95% CI 1.65–3.53) for private insurance and OR 1.43 (95% CI 1.01–2.01) for Medicare.
Methods
- Observational cross-sectional analysis of 2018–2019 MEPS data; participants were adults ≥ 18 years with self-reported diabetes.
- Insurance was classified as private, Medicare, or Medicaid based on ≥ 7 months of coverage; the outcome was receipt of ≥ 1 SGLT2i or GLP1ra in a calendar year.
- The main analysis used survey-weighted multivariable logistic regression with a race/ethnicity × payer interaction, then sequentially adjusted for cardiovascular risk, socioeconomic status, and healthcare access factors.
Limitations
- The paper states it could not further disaggregate race/ethnicity in adjusted analyses because of insufficient sample size, and could not capture within-payer variation in formularies or cost-sharing.
- It also states it could not distinguish type 1 from type 2 diabetes, and lacked reliable data on some comorbidities, labs, and insulin use.
- Evident from the text: because the study is cross-sectional and based on self-reported survey data, it cannot establish causality and may be subject to measurement limitations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
14 Valid · 2 Not valid · 3 Not checked · 45 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Although > 80% of patients with type 2 diabetes are eligible for these medications due to the presence of cardiovascular or renal risk factors, only 1 in 10 patients receives either an SGLT2i or GLP1ra medication.12,13”
§ Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study > BACKGROUND
What the sources say
- Disputedcites [12] Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. Journal of the American Heart Association. 2021;10(13):e021084. https://doi.org/10.1161/JAHA.121.021084 sourceExperimental — accuracy not yet measured
The Results section (Use of SGLT‐2 Inhibitors and GLP‐1RAs From 2017 to 2018) reports use of 4.5% and 1.5%, respectively, with 0.2% receiving both. That implies approximately 5.8% received either medication—closer to 1 in 17 than 1 in 10. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [13] Tang S, Shao H, Ali MK, Zhang P. Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Annals of Internal Medicine. 2023;176(4):582-583. https://doi.org/10.7326/m22-3051 %m 36848654 doi:10.7326/m22-3051/m36848654
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Although > 80% of patients with type 2 diabetes are eligible for these medications due to the presence of cardiovascular or renal risk factors, only 1 in 10 patients receives either an SGLT2i or GLP1ra medication.12,13”
§ Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study > BACKGROUND
What the sources say
- Disputedcites [12] Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. Journal of the American Heart Association. 2021;10(13):e021084. https://doi.org/10.1161/JAHA.121.021084 sourceExperimental — accuracy not yet measured
The Results section reports that 52.6% of patients had an indication for SGLT2 inhibitors, 32.8% for GLP-1RAs, and 26.6% for both. Accounting for the overlap, 58.8% were eligible for either medication—not more than 80%. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [13] Tang S, Shao H, Ali MK, Zhang P. Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Annals of Internal Medicine. 2023;176(4):582-583. https://doi.org/10.7326/m22-3051 %m 36848654 doi:10.7326/m22-3051/m36848654
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our findings, other studies have demonstrated low rates of SGLT2i and GLP1ra medication use (11.2% and 8%, respectively), even among patients at high risk of cardiovascular disease.12–16,32”
§ Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study > DISCUSSION In this nationally representative cohort study, we found considerable racial/ethnic disparities in the receipt of novel diabetes medications that were dependent on the type of insurance. White individuals with private insurance had more than double the medication use of non-White privately insured individuals. This disparity persisted after adjustment for cardiovascular risk, socioeconomic status, and access to care. A similar pattern of disparities, though much smaller in magnitude, was seen for Medicare beneficiaries. Although we found no significant differences in use among Medicaid enrollees by race/ethnicity, overall medication rates were the lowest versus individuals with private insurance or Medicare. However, we cannot exclude a possibility of either meaningfully lower or higher medication use among non-White Medicaid enrollees given wide confidence intervals. Because the magnitude of the disparity in medication use between White and non-White populations depended on the type of insurance, one potential key lever to improve health equity for individuals with diabetes is to address insurance plan policies that restrict access to novel diabetes medications, such as high out-of-pocket costs and formulary restrictions, to increase use of these highly effective medications for diabetes. Our findings may have even broader implications for pharmacoequity beyond diabetes given the expanding evidence base supporting the benefit of these medications in other conditions that affect large segments of the US population, including obesity, congestive heart failure, and chronic kidney disease.28–31 Consistent with our findings, other studies have demonstrated low rates of SGLT2i and GLP1ra medication use (11.2% and 8%, respectively), even among patients at high risk of cardiovascular disease.12–16,32 Recent studies have also broadly shown racial and ethnic differences in SGLT2i and GLP1ra prescriptions with Black, Hispanic/Latinx, and Asian groups receiving these medications at lower rates than White individuals.14–17 Our findings from this nationally representative sample extend the existing literature by showing that the extent of racial/ethnic disparities in receipt of novel diabetes medications depends on the type of insurance—worst for private insurance and potentially nonexistent for Medicaid. Differences in medication formularies and cost-sharing are potential drivers of use and observed racial/ethnic disparities in SGLT2i and GLP1ra medications between payers.18,21,33 Medicare plans have the greatest coverage of SGLT2i medications without prior authorization or step therapy, whereas Medicaid plans have the most restrictions to access.21 Conversely, Medicaid plans consistently have the lowest out-of-pocket costs.19,21–23,34 Thus, our findings imply that formulary access restrictions may influence overall prescription rates (highest in private insurance and Medicare but lowest in Medicaid), but cost-sharing may be most culpable in driving racial/ethnic disparities. Namely, the low but equitable prescription rates in Medicaid may be due to restricted access and low cost-sharing, respectively. These findings have practical implications for policy solutions that target practices at the insurance plan level to reduce high out-of-pocket costs and remove formulary restrictions. In doing so, it may be possible to reduce disparities in SGLT2i and GLP1ra use to achieve pharmacoequity and ultimately decrease racial/ethnic disparities in diabetes health outcomes.31 There is also wide variability within insurance types in terms of cost-sharing and formulary restrictions, which we were unable to explore in this study.18,22,33 For example, with regard to cost-sharing, co-payments and co-insurance are far more variable among private insurance plans than Medicare, in contrast to the nearly uniformly low out-of-pocket costs for Medicaid plans.21 The persistent racial/ethnic disparity we observed for private insurance may be explained by lower quality of coverage among privately insured minoritized populations who may face higher out-of-pocket costs and more restrictive formularies.35 This might also account for why medication use among non-White individuals with private insurance approached those of the Medicaid enrollees in our study. Regarding formulary restrictions, two-thirds of fee-for-service Medicaid beneficiaries have unrestricted access to an SGLT2i or GLP1ra medication versus just one-third of managed care Medicaid enrollees, with significant variation in access both across and within states.33 Future research should explicitly study the link between out-of-pocket costs for patients, formulary restrictions, and receipt of an SGLT2i or GLP1ra medication versus a dipeptidyl peptidase-4 inhibitor as a negative control, which are also novel diabetes medications but lack cardiovascular or mortality benefit. Another potential explanation for why we observed starkly different disparities by insurance type includes structural racism embedded in health systems, and implicit or explicit bias among the clinicians that may serve these different populations.17,35–37 However, the differential pattern by payer suggests that differences in insurance plan may be bigger drivers of disparities than health system- or clinician-level factors. Our study had certain limitations. First, we were unable to further disaggregate race/ethnicity in adjusted analyses due to insufficient sample size in the MEPS cohort. However, our unadjusted analyses confirmed a similar pattern in the magnitude of racial/ethnic disparities being largest for private insurance and smallest for Medicaid. Second, our insurance categories illustrate broad patterns in medication prescriptions but are unable to capture the variability of plan formularies and cost-sharing implications within payers. Third, we were unable to distinguish between type 1 and type 2 diabetes mellitus from data available in MEPS. Given the low national prevalence of type 1 diabetes, this is unlikely to meaningfully affect our estimates. Additionally, there is emerging data that SGLT2is may also be beneficial in type 1 diabetes.38,39 Fourth, we lacked reliable data on additional comorbidities (i.e., heart failure, chronic kidney disease, or strokes), laboratory measures (i.e., glucose, hemoglobin A1c, creatinine, microalbuminuria), and medications (i.e., insulin) that signify greater cardiovascular risk or worse diabetes control. Finally, contemporary medication rates are likely higher than those found in our study period from 2018 to 2019 given increased awareness and stronger practice guideline recommendations for individuals at higher cardiovascular risk without established CAD. While our descriptive findings show narrower disparities for individuals with diabetes and prior CAD, it is possible that racial and ethnic disparities are still present despite higher overall medication use. In conclusion, racial and ethnic disparities in novel diabetes medication use differ by insurance, with the greatest disparities observed among those with private insurance and which persist after adjusting for cardiovascular, socioeconomic status, and access to care factors. Disparities in medication use were the lowest in Medicaid and were not statistically significant; however, overall medication use was far lower among those with Medicaid than those with Medicare or private insurance. These findings suggest differences may be driven by different plan formulary and cost-sharing policies, which are potential policy levers to improve health equity.
What the sources say
- Partly supportedcites [12] Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. Journal of the American Heart Association. 2021;10(13):e021084. https://doi.org/10.1161/JAHA.121.021084 sourceExperimental — accuracy not yet measured
The Results section, “Use of SGLT-2 Inhibitors and GLP-1RAs From 2017 to 2018” (page unavailable), supports low use among eligible patients, including those with cardiovascular indications. It reports 7.0% SGLT2i use and 1.3% GLP-1RA use among eligible patients—not the attributed 11.2% and 8%. The Discussion mentions an approximately 8%–9% GLP-1RA rate from a prior registry, not this study’s estimate. (LLM, conf=0.88)
- Not checked yetcites [13] Tang S, Shao H, Ali MK, Zhang P. Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Annals of Internal Medicine. 2023;176(4):582-583. https://doi.org/10.7326/m22-3051 %m 36848654 doi:10.7326/m22-3051/m36848654
- Partly supportedcites [14] Eberly LA, Yang L, Eneanya ND, et al. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Network Open. 2021;4(4):e216139-e216139. https://doi.org/10.1001/jamanetworkopen.2021.6139 sourceExperimental — accuracy not yet measured
The Discussion and Conclusions report low SGLT2 inhibitor use even among patients with HFrEF or ASCVD. The Results give 11.9% SGLT2 inhibitor use in the full cohort in 2019, not 11.2%, and the paper does not report the claimed 8% GLP-1 receptor agonist use. (LLM, conf=0.88)
- Partly supportedcites [15] Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182-e214182. https://doi.org/10.1001/jamahealthforum.2021.4182 sourceExperimental — accuracy not yet measured
The Results report GLP-1 RA use in 7.7% of patients with type 2 diabetes, approximately the cited 8%, and low use among patients with ASCVD (9.4% in 2019). The paper does not report the claimed 11.2% SGLT2 inhibitor use, so it supports only the GLP-1 RA portion of the sentence. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [16] Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA. 2022;328(9):861-871. https://doi.org/10.1001/jama.2022.13885 source
- Supportedcites [32] Mahtta D, Ramsey DJ, Lee MT, et al. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022;45(2):372-380. https://doi.org/10.2337/dc21-1815 source
The Baseline Characteristics section reports SGLT2i use of 11.2% and GLP-1 RA use of 8.0% among patients with established atherosclerotic cardiovascular disease and type 2 diabetes. The Conclusions characterize utilization as low. The reported rates are for this VA cohort, not for all patients at cardiovascular risk. (LLM, conf=0.94)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Compounding this significant underuse, Black, Hispanic/Latinx, and Asian individuals receive fewer prescriptions for these medications compared to White individuals.14–17”
§ Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study > BACKGROUND
What the sources say
- Partly supportedcites [14] Eberly LA, Yang L, Eneanya ND, et al. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Network Open. 2021;4(4):e216139-e216139. https://doi.org/10.1001/jamanetworkopen.2021.6139 sourceExperimental — accuracy not yet measured
The Results report lower SGLT2 inhibitor use for Black and Asian patients than White patients. The Discussion says this inequity was not present for Latinx patients overall, although the Results found a small difference in the metformin-treated subgroup. The paper studies SGLT2 inhibitors, not GLP-1 receptor agonists. (LLM, conf=0.90)
- Supportedcites [15] Eberly LA, Yang L, Essien UR, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182-e214182. https://doi.org/10.1001/jamahealthforum.2021.4182 source
The Results report lower GLP-1 RA use among Black, Hispanic, and Asian patients than White patients in both 2015 and 2019. The Discussion also identifies lower GLP-1 RA use for all three groups. This paper directly supports the GLP-1 RA portion of the multi-cited statement; it mentions SGLT2 inhibitor disparities as prior findings. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [16] Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA. 2022;328(9):861-871. https://doi.org/10.1001/jama.2022.13885 source
- Partly supportedcites [17] Cai C, Woolhandler S, McCormick D, et al. Racial and Ethnic Inequities in Diabetes Pharmacotherapy: Black and Hispanic Patients Are Less Likely to Receive SGLT2is and GLP1as. Journal of General Internal Medicine. 2022/10/01 2022;37(13):3501-3503. https://doi.org/10.1007/s11606-022-07428-1 sourceExperimental — accuracy not yet measured
The Results report lower odds of receiving both SGLT2is and GLP1as for Black and Hispanic individuals compared with White individuals. The Discussion states that sample-size constraints precluded analyses of other racial or ethnic groups, so this paper does not support the claim about Asian individuals. Page numbers are not available in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
§ Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study > BACKGROUND
What the sources say
- Partly supportedcites [4] Odutayo A, Costa BRd, Pereira TV, et al. Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression. Journal of the American Heart Association. 2021;10(18):e019918. https://doi.org/10.1161/JAHA.120.019918 sourceExperimental — accuracy not yet measured
The Results (All-Cause and Cardiovascular Mortality; page unavailable) report evidence of reduced cardiovascular mortality for three SGLT2 inhibitors, but little evidence for two others. The paper does not establish that the mortality benefit is independent of glucose lowering, and it does not evaluate GLP-1 receptor agonists. Its Discussion addresses guideline recommendations for SGLT2 inhibitors, not both drug classes. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [5] Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. Oct 2019;7(10):776-785. https://doi.org/10.1016/s2213-8587(19)30249-9 source
- Partly supportedcites [6] McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technol Ther. Dec 2019;21(12):702-712. https://doi.org/10.1089/dia.2019.0213 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports improved cardiovascular outcomes with SGLT2 inhibitors and says guidelines recommend their use in selected clinical contexts. It does not establish a significant reduction in cardiovascular deaths independent of glucose lowering, or make that claim for GLP-1 receptor agonists, which the Discussion mentions only as a comparator class. (LLM, conf=0.86)
- Partly supportedcites [7] Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgraduate Medical Journal. 2020;96(1133):156-161. https://doi.org/10.1136/postgradmedj-2019-137186 sourceExperimental — accuracy not yet measured
The LEADER section reports significantly fewer cardiovascular deaths with liraglutide than with placebo, and the guidelines discussion recommends considering GLP-1 RAs or SGLT2 inhibitors for some patients with type 2 diabetes. But the paper does not establish a cardiovascular-death reduction for both drug classes independent of glucose lowering; its SUSTAIN-6 section explicitly questions whether semaglutide’s cardiovascular benefit came from the drug itself or improved glycaemic control. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Makam AN, Nguyen OK. An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment. Circulation. 2017;135(2):180-195. https://doi.org/10.1161/CIRCULATIONAHA.116.022622 sourceExperimental — accuracy not yet measured
In “What are the estimated benefits of intensive glycemic control in type 2 diabetes?”, the paper reports clinically significant reductions in cardiovascular mortality in trials of empagliflozin and liraglutide. It says the reductions were likely not mediated by intensive glycemic control, but treats that mechanism as an inference; the claim states independence as fact and extends findings from two drugs to their entire classes. (LLM, conf=0.87)
- Partly supportedcites [9] 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care. Jan 2020;43(Suppl 1):S111-s134. https://doi.org/10.2337/dc20-S010 sourceExperimental — accuracy not yet measured
The GLP-1 Receptor Agonist Trials section reports significant reductions in cardiovascular events with several SGLT2 inhibitors and GLP-1 receptor agonists, and recommends agents with demonstrated cardiovascular benefit for selected patients with type 2 diabetes. It does not establish that both classes significantly reduce cardiovascular deaths specifically or that those benefits are independent of their effects on hyperglycemia; the SGLT2 Inhibitor Trials section reports no difference in cardiovascular death in one trial. Page numbers were not available in our copy. (LLM, conf=0.87)
- Partly supportedcites [10] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022/05/03/ 2022;79(17):e263-e421. https://doi.org/10.1016/j.jacc.2021.12.012 sourceExperimental — accuracy not yet measured
Section 7.3.4 (page not supplied) reports reduced cardiovascular death with SGLT2i therapy in heart-failure trials, with benefits seen irrespective of baseline diabetes status; it also says the heart-failure benefit appears independent of glucose lowering. The cited passages do not establish that cardiovascular-death reduction itself is independent of glucose lowering, and they do not report a cardiovascular-death benefit or guideline endorsement for GLP-1 receptor agonists. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] Navaneethan SD, Zoungas S, M. Luiza Caramori ea. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Annals of Internal Medicine. 2023;176(3):381–387. https://doi.org/10.7326/m22-2904 %m 36623286 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
28 more claims · 4 with their cited sources checked
Create a free account to see all 64 claims and to verify the 5 references still open.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 21
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Structural racism and health inequities in the USA: evidence and interventions
Bailey, Z. D., Krieger, N., Agénor, M., Graves, J., Linos, N., & Bassett, M. T. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30569-x · Cited by 5,203
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Inequality and the health-care system in the USA
Dickman, S. L., Himmelstein, D. U., & Woolhandler, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30398-7 · Cited by 656
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417 · cited 1×
“38,39 Fourth, we lacked reliable data on additional comorbidities (i.e., heart failure, chronic kidney disease, or strokes), laboratory measures (i.e., glucose,”
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Cited by
Bazzazzadehgan, S., Shariat‐Madar, Z., & Mahdi, F. (2025) · Biomolecules · doi:10.3390/biom15030414 · Cited by 21
Friesch, M., Fernando, M., Sheedy, E. F., Helenowski, I., Wool, L., Edwards, M., Brown, K. R., Lau, J. N., & Cohn, T. D. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11838-7 · Cited by 12
“In the context of severe DM2, the relative superiority of RYGB to induce DM resolution when compared to SG is mitigated [9], which may have impacted procedure selection.”
Moore, J. A., Iheme, N., Rebold, N., Kusi, H., Mere, C., Nwaogwugwu, U., Ettienne, E. B., Chaijamorn, W., & Rungkitwattanakul, D. “. (2025) · Pharmacy · doi:10.3390/pharmacy13020046 · Cited by 12
The forgotten - overcoming challenges in diabetes care for marginalized populations
Martinez-Cruz, M., Namasingh, N., Alexopoulos, A., Batch, B. C., Crowley, M. J., & Bosworth, H. B. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2526200 · Cited by 9
“Similar findings have been reported in a cohort of patients from racial minorities who had private insurance and Medicare [34].”
Müller, F., Bouthillier, M. J., Alshaarawy, O., Azhary, H., & Holman, H. T. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6656982 · Cited by 3
“Medicare, Medicaid, and private insurance each implement distinct formulary restrictions, prior authorization requirements, and cost-sharing structures that can create signi fi cant access barriers, with pronounced disparities a ff ecting racial and ethnic minorities [12, 13].”
Metadata
- Authors
- Bepo, L., Nguyen, O. K., & Makam, A. N.
- Affiliations
- San Francisco General Hospital (US)
- Corresponding author
- Bepo, Lurit
- Venue
- Journal of General Internal Medicine
- Published
- 2024-07-31
- Volume
- 39
- Issue
- 15
- Pages
- 2987-2994
- ISSN
- 0884-8734 (ISSN-L)
- 1525-1497
- PMC
- PMC11576692
- OpenAlex
- W4401169921
- Cited by
- 20
- References
- 36
- Citations by year
- 2026: 10 · 2025: 10
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of General Internal Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Health Resources and Services Administration (T32HP19025)
- National Heart, Lung, and Blood Institute (K23HL133441)
- National Institute on Aging (K23AG052603)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Health › Health disparities and outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, racial and ethnic disparities, SGLT2 inhibitors, GLP-1 receptor agonists, insurance coverage, Medicare, Medicaid, private insurance, access to medicines, cost sharing, prior authorization, formulary restrictions, Hispanic population, prescription rates, Medical Expenditure Panel Survey, health equity, cardiovascular risk reduction, health care access, socioeconomic factors
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Female, Medicare, Humans, Hypoglycemic Agents, Insurance, Health, Male, Medicaid, Middle Aged, United States, Cohort Studies, Insurance Coverage, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study. https://app.cochat.ai/papers/10.1007/s11606-024-08961-x
- The paper
- Bepo, L., Nguyen, O. K., & Makam, A. N. (2024). Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-024-08961-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.